FOLH1 and prostate carcinoma: The cytotoxicity of GZMB-MU2 was assessed using the previously characterized human prostate cancer cell line PC-3 engineered to express PSMA (PIP) or vector control (Flu) and the PSMA-expressing human prostate cancer cell lines LNCaP and CWR22Rv1.